Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01334307
Other study ID # CLN0008
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date February 2010
Est. completion date September 2013

Study information

Verified date July 2021
Source Boston Scientific Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to demonstrate the safety and performance of the PneumRx, Inc. Lung Volume Reduction Coil (LVRC) in a population of patients with emphysema. The PneumRx, Inc. LVRC is used as a less invasive alternative to lung volume reduction surgery.


Recruitment information / eligibility

Status Completed
Enrollment 47
Est. completion date September 2013
Est. primary completion date June 2013
Accepts healthy volunteers No
Gender All
Age group 35 Years and older
Eligibility Inclusion Criteria: - Patient greater than or equal to 35 years of age - High resolution CT scan indicates unilateral or bilateral emphysema - High resolution CT scan indicates homogeneous or heterogeneous emphysema - Patient has post-bronchodilator FEV1 less than or equal to 45% predicted - Total Lung Capacity greater than 100% predicted - Patient has marked dyspnea scoring greater than or equal to 2 on mMRC scale of 0-4 - Patient has stopped smoking for a minimum of 8 weeks prior to entering the study - Patient (and legal guardian if applicable) read, understood and signed the Informed Consent form Exclusion Criteria: - Patient has a change in FEV1 greater than 20% post-bronchodilator - Patients DLCO less than 20% predicted - Patient has a history of recurrent clinically significant respiratory infection - Patient has uncontrolled pulmonary hypertension defined by right ventricular pressure greater than 50mm Hg and/or evidenced by echocardiogram - Patient has an inability to walk greater than 140 meters (150 yards) in 6 minutes - Patient has evidence of other disease that may compromise survival such as lung cancer, renal failure, etc - Patient is pregnant or lactating - Patient has an inability to tolerate bronchoscopy under heavy sedation or anesthesia - Patient has clinically significant bronchiectasis - Patient has giant bullae greater than 1/3 lung volume - Patient has had previous LVR surgery, lung transplant or lobectomy - Patient has been involved in other pulmonary drug studies with 30 days prior to this study - Patient is taking greater than 20 mg prednisone (or similar steroid) daily - Patient is on Plavix or has not been weaned off prior to procedure - Patient has other disease that would interfere with completion of study, follow up assessments or that would adversely affect outcomes

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Lung Volume Reduction Coil (LVRC) (PneumRx)
Lung Volume Reduction Coil (LVRC)
Control
Standard of Care

Locations

Country Name City State
United Kingdom Chelsea and Westminster Hospital London

Sponsors (2)

Lead Sponsor Collaborator
Boston Scientific Corporation PneumRx, Inc.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary St. George's Respiratory Questionnaire (SGRQ) The primary efficacy endpoint will be the difference between treatment and control groups in the change in St. George's Respiratory Questionnaire (SGRQ) from Baseline (Pre-Treatment Visit) to the three month Follow-Up Visit. three month Follow-Up Visit
See also
  Status Clinical Trial Phase
Recruiting NCT05825261 - Exploring Novel Biomarkers for Emphysema Detection
Completed NCT02999685 - Home-based Health Management of Chronic Obstructive Lung Disease (COPD) Patients N/A
Completed NCT02914340 - REACH SVS Control Patient Cross-Over Study N/A
Completed NCT02238327 - Longitudinal Evaluation of HIV-associated Lung Disease Phenotypes
Completed NCT02232841 - Electrical Impedance Imaging of Patients on Mechanical Ventilation N/A
Completed NCT01615484 - Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability N/A
Withdrawn NCT01908933 - Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema Phase 3
Completed NCT01476995 - Prognostic Indicators as Provided by the EPIC ClearView N/A
Completed NCT01710449 - Evaluation of Regional Ventilation Using 19F MRI of Inert Perfluorinated Gases Mixed With Oxygen Phase 1
Suspended NCT00523094 - Vibration Response Imaging (VRI) in Patients That Are Candidates for Undergoing Pulmonary Operation Procedure N/A
Completed NCT00475007 - Clinical Trial to Evaluate the Safety and Effectiveness of the IBV® Valve System for the Treatment of Severe Emphysema N/A
Recruiting NCT00129350 - Assessment of Heart and Heart-Lung Transplant Patient Outcomes Following Pulmonary Rehabilitation Phase 1
Completed NCT01953523 - Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions N/A
Completed NCT00000621 - Feasibility of Retinoic Acid Treatment in Emphysema (FORTE) Phase 2
Completed NCT00005292 - Alpha1-antitrypsin Deficiency Registry N/A
Recruiting NCT04537182 - Surgical Compared to Bronchoscopic Lung Volume Reduction in Patients With Severe Emphysema N/A
Active, not recruiting NCT02713347 - Advancing Symptom Alleviation With Palliative Treatment N/A
Recruiting NCT04302272 - STRIVE Post-Market Registry Study
Completed NCT04435327 - Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
Completed NCT03636347 - A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo. Phase 2